Sanofi-Aventis (France) (SASY.PA) Agrees to Acquire TargeGen, Inc. for $75 Million Upfront; May Spend as Much as $560 Million on Milestone Payments
6/30/2010 7:34:33 AM
More...
|
TargeGen, Inc. Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients
10/23/2009 8:17:42 AM
More...
|
TargeGen, Inc. Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
5/15/2009 8:49:14 AM
More...
|
TargeGen, Inc. Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 American Society of Hematology Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
12/2/2008 8:50:24 AM
More...
|
Partnership Between Industry And Academia Has Led To Human Clinical Trials Of A New Drug; Stem Cell Research Leads To Potential New Therapy For Rare Blood Disorder
4/10/2008 8:12:41 AM
More...
|
TargeGen, Inc. Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
2/1/2008 7:29:10 AM
More...
|
TargeGen, Inc. Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
12/7/2007 6:31:02 AM
More...
|
TargeGen, Inc. Initiates Multi-Center Phase II Clinical Trial Of TG100801, a Topically Applied Kinase Inhibitor In Macular Degeneration Patients
7/30/2007 12:41:11 PM
More...
|
TargeGen, Inc. Closes $40M Series 'D' Financing Round
7/12/2007 11:05:48 AM
More...
|
TargeGen, Inc. Receives 2007 James D. Watson Helix Award in the Private Company Category
5/9/2007 12:06:53 PM
More...
|
|